Kyinno Biotechnology

Established in 2017 and based in Beijing, China, Kyinno Biotechnology is a biotechnology company that focuses on research and development of tumor immunity and next-generation kinase inhibition. The company has 1,500 square meters Company floor area and 50 employees. The company has completed 3 rounds of funding as of 2021. In February 2025, Kyinno Biotechnology raised a series B funding from new investors E-Town International Industrial Investment and Beijing Pharmaceutical and Health Industry Investment Fund.

The company self-developed products include stable cell line products such as kinase cell line, immune molecules cell line, reporter cell line, gene editing cell line, luciferase cell line and customized product development, and benchmark antibody products such as Isotype, therapeutic antibody, hybridoma and customized antibody products. Besides, the company provides in vivo or in vitro study service and antibody discovery service such as humanization & affinity maturation service, immunogenicity evaluation service and developability assessment service for customers. The company generates revenue from providing cell line products (including engineered cell lines, cancer cell lines, and antibodies) and services (including in vivo service, in vitro service and antibody discovery service).